A pairing appears on this page only when a trial gave both ingredients together and measured the result. Adenosine triphosphate has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Free ATP is essentially not a substrate for most kinases and ATPases. Magnesium chelates the beta and gamma phosphates to form Mg-ATP, which is the form the enzyme actually binds and hydrolyses. This is one of the most settled relationships in biochemistry, and it is the reason magnesium status shows up in almost every discussion of cellular energy.
Phosphocreatine donates its phosphate to ADP through creatine kinase, regenerating ATP faster than any other route in the first seconds of intense effort. Loading creatine raises the phosphocreatine pool and so raises the size of that buffer. Supplemental ATP itself does not reach the muscle cytosol, so creatine is the practical way to influence the same pool.
ATP is adenine plus ribose plus three phosphates. De novo adenine nucleotide synthesis runs through phosphoribosyl pyrophosphate, which is built from ribose-5-phosphate, and that step is slow. Supplying ribose bypasses part of the rate limit on rebuilding a depleted nucleotide pool. Whether that translates into anything a person notices is a separate question and the human data is thin.
Ubiquinone shuttles electrons from complexes I and II to complex III, and that electron flow is what builds the proton gradient ATP synthase uses. Without adequate CoQ10 the gradient collapses and oxidative phosphorylation stalls. The relationship is upstream: CoQ10 supports the machinery that makes ATP rather than adding ATP directly.
Glycolysis and the TCA cycle capture energy as NADH, which complex I oxidises to start the electron flow that ends in ATP synthesis. The NAD pool has to be continuously regenerated or the whole chain backs up. This is why NAD precursors get discussed alongside cellular energy, though the link to any felt effect is not established.
Riboflavin becomes FAD and FMN, which sit inside complex I and complex II of the electron transport chain. Low riboflavin status impairs electron entry at both points. It is a cofactor relationship, so more riboflavin above sufficiency does not push output higher.
Pyruvate cannot enter the TCA cycle without pyruvate dehydrogenase, and that complex needs thiamine pyrophosphate. Deficiency shunts pyruvate to lactate and cuts off the main aerobic ATP route. Alpha-ketoglutarate dehydrogenase inside the cycle needs it too.
Lipoic acid is built into both of the big mitochondrial dehydrogenase complexes as lipoamide, where it carries the acyl group between subunits. Supplemental lipoic acid is not what supplies that bound cofactor, which the body synthesises, so the practical link to ATP output is weaker than the biochemistry suggests.
Long-chain fatty acids cannot cross into the mitochondrial matrix on their own. Carnitine palmitoyltransferase attaches them to carnitine for transport, and inside they are beta-oxidised to acetyl-CoA feeding ATP production. The step is obligatory, which is why primary carnitine deficiency presents as an energy-metabolism disorder.
Extracellular ATP is rapidly dephosphorylated to adenosine, which signals at A1 and A2A receptors and contributes to the sensation of fatigue. Caffeine blocks those receptors. Anyone reasoning about ATP as a signalling molecule rather than an energy currency should note the two act in opposite directions at that receptor.
ATP synthase condenses ADP with inorganic phosphate, so phosphate availability sets a hard ceiling on how fast ATP can be regenerated. Severe phosphate depletion produces measurable muscle weakness for exactly this reason. In people eating normally, phosphate is not the limiting factor.
Rapid glycolytic ATP turnover releases protons faster than the cell can buffer them, and the falling pH inhibits phosphofructokinase, which slows ATP regeneration further. Bicarbonate raises extracellular buffering and helps export those protons. It does not add ATP, it delays the point where acidosis limits it.
Beta-alanine is rate-limiting for carnosine synthesis, and carnosine buffers protons inside the muscle fibre where they are generated. That extends the window over which glycolysis can regenerate ATP at a high rate. The mechanism is buffering, not energy supply.
Alkaline phosphatase and related ecto-enzymes that hydrolyse extracellular ATP to ADP, AMP and adenosine are zinc metalloenzymes. Zinc status therefore affects how quickly an extracellular ATP signal is terminated. This is relevant to ATP as a signalling molecule and says nothing about intracellular energy stores.
Nothing specific on file for Adenosine triphosphate. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 6 we read for Adenosine triphosphate. The full linked list is below.
5 sources behind our Adenosine triphosphate verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Read this carefully. These are 1,128 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Adenosine triphosphate is, not how risky it is. A report is not proof Adenosine triphosphate caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.